Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05766748 | Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 30 | Cantex PharmaceuticalsINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05832892 | Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 41 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06018896 | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer(PTCA199-4) | unknown | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05304234 | Liver Cancer Disparities in American Indian and Alaska Native Persons | unknown | Phase 2 | 200 | University of WashingtonOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06436976 | The Effect of Probiotics ATG-F4 in Cancer Patients | unknown | Phase 2 | 30 | Chungnam National University HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06437678 | Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer | unknown | Phase 2 | 50 | Zhejiang Cancer HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434090 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 74 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT03714490 | MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer(SUNRISE) | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04799548 | A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma | unknown | Phase 2 | 71 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT03992456 | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | unknown | Phase 2 | 12 | Academic and Community Cancer Research UnitedOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06422156 | SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer(Nim-PC-28) | unknown | Phase 2 | 73 | Peking University Third HospitalOTHER | 0 | May 20, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06419140 | Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy | unknown | Phase 2 | 138 | Zhejiang Cancer HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04672005 | Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer | unknown | Phase 2 | 30 | Lyudmyla BerimOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06415851 | Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | unknown | Phase 2 | 36 | Zhangfa SongOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06148402 | Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT06408623 | Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer | unknown | Phase 2 | 48 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | May 10, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05965817 | Fluorescence-guided Resection Of Colorectal Liver Metastases Using SGM-101 and Indocyanine GREEN(FOCUS GREEN) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06403878 | Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer | unknown | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06404840 | Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06405685 | Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06078787 | Olaparib in PALB2 Advanced Pancreatic Cancer(PALBOLA) | unknown | Phase 2 | 16 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06398405 | A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer | unknown | Phase 2 | 72 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06395337 | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer(MIRCA & MIPAC) | unknown | Phase 1 / Phase 2 | 20 | Radboud University Medical CenterOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06392971 | Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis | unknown | Phase 2 | 120 | First Affiliated Hospital of Chengdu Medical CollegeOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06394128 | Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess | unknown | Phase 2 | 48 | First People's Hospital of HangzhouOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06206096 | PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC | unknown | Phase 2 | 40 | Chinese PLA General HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06383559 | Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT04301557 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT03579784 | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | unknown | Phase 2 | 40 | Do-Youn OhOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04298008 | AZD6738 Plus Durvalumab in Biliary Tract Cancer | unknown | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04298021 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | unknown | Phase 2 | 74 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04371224 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer(NaliCap) | unknown | Phase 2 | 200 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04447092 | Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | unknown | Phase 2 | 77 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04727996 | Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer(BTC-BGB) | unknown | Phase 2 | 43 | Seoul National University HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375486 | Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC). | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06233864 | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | unknown | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06370065 | Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04908813 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 150 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04776590 | Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer(CRISEC) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06014372 | Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer | unknown | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363552 | A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer | unknown | Phase 2 | 36 | Tianshu LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06364007 | HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC | unknown | Phase 2 | 20 | Sulai LiuOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06353581 | Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX | unknown | Phase 2 | 78 | Yonsei UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 14, 2024source: clinicaltrials